MedTrace Logo

Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Technology

NCT02942849 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1195

Last updated 2020-02-05

No results posted yet for this study

Summary

Prospective, non-comparative, multi-centre, multi-country, observational post-authorization study, to correlate predictive factors with number of oocytes in relation to the gonadotropin dose administered using a new r-hFSH product (Bemfola®) for ovarian stimulation and GnRH-antagonists for pituitary suppression

Conditions

Interventions

DRUG

r-hFSH

As per standard clinical practice

Sponsors & Collaborators

  • Finox AG

    lead INDUSTRY

Principal Investigators

  • Jan-Steffen Krüssel, MD · Leiter universitäres interdisziplinäres Kinderwunschzentrum Düsseldorf (UniKiD)

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02942849 on ClinicalTrials.gov